11 To 14 Amino Acid Residues In Defined Sequence Patents (Class 530/327)
  • Peptide-based tooth whitening reagents
    Patent number: 8481678
    Abstract: Peptide-based reagents comprising at least one tooth surface-binding peptide for delivery of at least one polymer-coated white colorant to the surface of teeth are provided. The peptide-based reagent may comprise at least one tooth-binding peptide coupled to, either directly or through one or more spacers, a polymer-binding peptide capable of binding to the polymeric coating on a polymer-coated white colorant. Methods of delivering a polymer-coated white colorant to a tooth surface are also provided as well as oral care compositions comprising the present peptide-based reagents. The peptide-based reagents may be used in conjunction with at least one polymer-coated white colorant to improve the cosmetic appearance of teeth.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: July 9, 2013
    Assignee: E I du Pont de Nemours and Company
    Inventors: Douglas Robert Anton, Scott D. Cunningham, Stephen R. Fahnestock, Kari A. Fosser, Hong Wang
  • Compounds for the treatment of diseases related to protein misfolding
    Patent number: 8481494
    Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: July 9, 2013
    Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
  • Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit
    Patent number: 8481332
    Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 9, 2013
    Assignee: Stichting Voor de Technische Wetenshappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Tag peptide having a protease recognition sequence and use thereof
    Patent number: 8481310
    Abstract: Provided is a tag peptide in which a protease recognition sequence and an epitope of an antibody against the tag peptide are overlapped and thereby the protease recognition sequence per se is usable for detection or purification. Also provided is a purification method for recombinant proteins using the tag peptide and an antibody thereagainst. A preferable tag peptide comprises a Tobacco etch virus (TEV) protease recognition sequence as the protease recognition sequence, and its examples include a tag peptide comprising the amino acid sequence (1): RX1X2LYX3QGKDG (wherein X1, X2 and X3 may be the same or different and represent any amino acid residue).
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: July 9, 2013
    Assignee: Osaka University
    Inventor: Junichi Takagi
  • GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20130172242
    Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.
    Type: Application
    Filed: June 16, 2011
    Publication date: July 4, 2013
    Applicants: MCGILL UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
  • Treating Stroke and Other Diseases Without Inhibiting N-Type Calcium Channels
    Publication number: 20130172230
    Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 4, 2013
    Applicants: Arbor Vita Corporation, NoNo Inc.
    Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
  • Immunogenic Peptides of Xage-1
    Publication number: 20130171178
    Abstract: XAGE-1 is a gene expressed in a number of important human cancers, including prostate cancer, lung cancer, breast cancer, ovarian cancer, glioblastoma, pancreatic cancer, and melanoma. It has now been discovered that peptides of fifty or fewer amino acids comprising the sequence X1X2X3PSAPSPX4 (SEQ ID NO:5), where X1 is any amino acid and is preferably G or Y; X2 is selected from the group consisting of L, M, A, I, V, and T, with L and M being preferred; X3 is a hydrophobic residue, M or A; and X4 is V, M, L, A, I, or T, and is preferably V, bind to the HLA-A2 MHC class I molecule, and can be used to raise immune responses to XAGE-1-expressing cancers. In some embodiments, the P at position 7, the S at position 8, or the P at position 9, can be omitted to create a 9 amino acid peptide.
    Type: Application
    Filed: December 13, 2004
    Publication date: July 4, 2013
    Applicant: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES
    Inventors: Jay A. Berzofsky, Ira H. Pastan, Masaki Terabe
  • Novel JNK Inhibitor Molecules
    Publication number: 20130172530
    Abstract: The present invention relates to novel JNK inhibitor molecules. The present invention furthermore relates to methods for raising antibodies against such JNK inhibitor molecules as well as to the respective antibodies and cells producing said antibodies.
    Type: Application
    Filed: June 21, 2011
    Publication date: July 4, 2013
    Applicant: XIGEN S.A.
    Inventor: Christophe Bonny
  • Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof
    Publication number: 20130172272
    Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.
    Type: Application
    Filed: February 20, 2013
    Publication date: July 4, 2013
    Applicant: Medical Diagnostic Laboratories
    Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
  • Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
    Patent number: 8476408
    Abstract: The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1; and to pharmaceutical compositions comprising unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: July 2, 2013
    Assignee: Alize Pharma SAS
    Inventors: Maria Brizzi, Giampiero Muccioli, Ezio Ghigo
  • Vaccines - Screening Method
    Publication number: 20130164315
    Abstract: The present invention provides a screening method for identifying a peptide capable of inducing a T cell response comprising: a) contacting a peptide having a level of identity with a sequence of a protein of a virus, with a test sample comprising T cells obtained from blood from a subject who is currently or has been recently infected with the virus, b) quantifying the response of the T cells to the peptide, c) comparing the T cells' response in b) to a response of a control sample comprising T cells obtained from blood from a subject who is not currently infected nor been recently infected with the virus, when contacted with the peptide, wherein a greater response to the peptide in b) than in c) is indicative of a peptide capable of inducing a T cell response.
    Type: Application
    Filed: December 23, 2011
    Publication date: June 27, 2013
    Applicants: University of Southampton, Retroscreen Virology
    Inventors: Robert Lambkin-Williams, John S. Oxford, Thomas Wilkinson
  • Selective Binding Compounds
    Publication number: 20130165624
    Abstract: Compounds which can include an active (drug) moiety have the general formula (I): wherein: SA is a pentapeptide aa1-aa2-aa3-aa4-aa5, wherein at least one of aa1, aa2, aa3, aa4, and aa5 is L, I, E, D, and I, respectively, wherein L, I, E, and D are eponymous amino acids; SB is a dipeptide aa6-aa7, wherein at least one of aa6 and aa7 is L and W, respectively, wherein W and L are eponymous amino acids; R1 and R5 are N-, and C-terminal moieties, respectively; R3 and R4 are independently a linker selected from a substituted or unsubstituted methylene, an amino acid, a peptide, and a peptide bond; and S is a scaffold moiety, a bond, a peptide bond, an amino acid, or a peptide of up to three residues, wherein R3, S, and R4 together form a turn in the compound, and the compound selectively binds a serum albumin.
    Type: Application
    Filed: December 22, 2012
    Publication date: June 27, 2013
    Applicant: SRI INTERNATIONAL
    Inventor: Hendrik Mario Geysen
  • Method of Producing a Paralytic Peptide
    Publication number: 20130165388
    Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.
    Type: Application
    Filed: December 21, 2012
    Publication date: June 27, 2013
    Applicant: SORICIMED BIOPHARMA INC.
    Inventor: Soricimed Biopharma Inc.
  • Leptin agonist and methods of use
    Patent number: 8470772
    Abstract: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, insulin resistance, lipodystrophy and hypothalamic amenorrhea, anorexia-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: June 25, 2013
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Eva Surmacz, Laszlo Otvos, Jr.
  • VIP fragments and methods of use
    Patent number: 8470778
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorders.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: June 25, 2013
    Assignee: Vectus Biosystems Limited
    Inventor: Karen Annette Duggan
  • Multifunctional compounds for pharmaceutical purposes
    Patent number: 8470963
    Abstract: The invention relates to a synthetic bifunctional non-antibody compound comprising one or more effector moieties and one or more binder moieties, wherein the effector moieties are operably linked to the binder moieties via a linker, the effector moieties are ligands to at least one pathogen pattern recognition receptor (PRR) and the binder moieties bind to a marker of a tumor cell.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: June 25, 2013
    Assignee: Sku Asset Management GmbH
    Inventor: Andre Koltermann
  • HCV NS5B PROTEASE MUTANTS
    Publication number: 20130157258
    Abstract: The invention provides polypeptides comprising an amino acid sequence comprising at least one variation from wild-type HCV NS5B polymerase, the at least one variation selected from the group consisting of cysteine, isoleucine, valine, or proline at amino acid position 419; alanine, valine, or asparagine at amino acid position 482; valine, isoleucine, threonine, or serine at amino acid position 486; and isoleucine at amino acid position 494, as the amino acid positions are defined in SEQ ID NO: 1, and having Hepatitis C Virus (HCV) NS5B polymerase activity. Polynucleotides encoding the polypeptide, antibodies, host cells, compositions, and methods for detecting an HCV NS5B polymerase having resistance to a polymerase inhibitor also are provided.
    Type: Application
    Filed: June 15, 2011
    Publication date: June 20, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Douglas J. Bartels, Min Jiang, Tara Lynn Kieffer, Olivier Nicolas
  • RHAMM BINDING PEPTIDES
    Publication number: 20130157338
    Abstract: The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.
    Type: Application
    Filed: May 31, 2011
    Publication date: June 20, 2013
    Inventors: Leonard G. Luyt, Eva A. Turley, Kenneth Virgel Esguerra
  • ISOLATION OF MESENCHYMAL STEM CELLS
    Publication number: 20130156819
    Abstract: The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues.
    Type: Application
    Filed: December 5, 2012
    Publication date: June 20, 2013
    Applicants: Baden-Württemberg Stiftung gGmbH, Eberhard-Karls-Universit°t Tübingen Universit°tsklinikum
    Inventors: Eberhard-Karls-Universit°t Tübingen Universit°tskl, Baden-Württemberg Stiftung gGmbH
  • LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE
    Publication number: 20130157961
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 20, 2013
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter
  • Novel Peptides for Wound Healing
    Publication number: 20130157949
    Abstract: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition comprising them and their use for wound healing.
    Type: Application
    Filed: June 14, 2011
    Publication date: June 20, 2013
    Applicant: GENE SIGNAL INTERNATIONAL SA
    Inventors: Salman Al-Mahmood, Sylvie Colin
  • Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
    Patent number: 8466258
    Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E (SEQ ID NO: 1) wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: June 18, 2013
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Universite Paris Diderot—Paris 7
    Inventors: Martine Jandrot-Perrus, Julien Muzard, Philippe Billiald, Dominique le Guludec, Laure Sarda, Alain Meulemans
  • Polypeptides for the Treatment or Prevention of Cancer and uses Thereof
    Publication number: 20130149372
    Abstract: Disclosed herein are polypeptides or their derivatives and their application. The polypeptides and their derivatives can treat or prevent cancer. The polypeptides of the invention have significant lethality to the cancer cells when used alone. When its clinical commonly used chemotherapy drugs such as cisplatin in combination, it can significantly increase the sensitivity of chemotherapeutic agents on cancer cells, to enhance its lethality of cancer cells, to reduce the dosage. The peptides can kill a variety of cancer cells, but without apparent toxicity enhancing effect on normal cells. The prepared peptides of the present invention can be chemically synthesized, high-purity, low molecular weight, specificity, non-immunogenic, safe and reliable.
    Type: Application
    Filed: September 29, 2010
    Publication date: June 13, 2013
    Applicant: WUHAN KATYGEN PHARMACEUTICALS,INC.
    Inventors: Jianhua Chen, Yi Huang, Junyu Xiong, Caihong Chen
  • NOVEL REGULATORY PROTEINS AND INHIBITORS
    Publication number: 20130149309
    Abstract: The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates ?-secretase to produce ?-amyloid protein (A?). Deposition of A? has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of A?.
    Type: Application
    Filed: February 6, 2012
    Publication date: June 13, 2013
    Inventors: Paul Greengard, Gen He, Peng Li, Wenjie Luo, Lawrence P. Wennogle
  • AVß6 PEPTIDE LIGANDS AND THEIR USES
    Publication number: 20130149248
    Abstract: AV?6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV?6 mediated diseases.
    Type: Application
    Filed: January 17, 2013
    Publication date: June 13, 2013
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventor: CANCER RESEARCH TECHNOLOGY LIMITED
  • Novel Peptides and Uses Thereof
    Publication number: 20130149245
    Abstract: The invention relates to a peptide of 8-50 amino acids comprising the sequence of KAHKKRAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising the sequence of HKKR or RKKH. Also disclosed are methods of using the peptide for detecting, monitoring, or treating cancer.
    Type: Application
    Filed: September 20, 2012
    Publication date: June 13, 2013
    Applicants: CHILDREN'S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: UNIVERSITY OF SOUTHERN CALIFORNIA, CHILDREN'S HOSPITAL LOS ANGLES
  • Agents that modulate Eph receptor activity
    Patent number: 8461119
    Abstract: Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: June 11, 2013
    Assignee: The Burnham Institute
    Inventors: Elena B. Pasquale, Mitchell Koolpe, Keith K. Murai
  • AGENTS FOR TREATING ALZHEIMER'S DISEASE
    Publication number: 20130143822
    Abstract: Agents for treating Alzheimer's disease comprising a peptide according to sequence no. 1 which binds to A? oligomers and thus results in the healing or alleviation of Alzheimer's disease. In further embodiments peptides are provided which contain a sequence no. 1, but have preceding sequence sections which allow the peptide to be secreted. For the purpose of gene therapy, corresponding DNA sequences and vectors, in particular according to sequences 3 to 6, are provided.
    Type: Application
    Filed: April 9, 2011
    Publication date: June 6, 2013
    Inventors: Susanne Aileen Funke, Luitgard Nagel-Steger, Dirk Bartnik, Olexandr Brener, Torsten Sehl, Katja Wiesehan, Dieter Willbold
  • CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER TREATMENT AND DIAGNOSIS
    Publication number: 20130142867
    Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.
    Type: Application
    Filed: October 25, 2011
    Publication date: June 6, 2013
    Applicant: Academia Sinica
    Inventors: John Yu, Alice L. Yu, H.C. Wu, I-Ju Chen, Sheng-Hung Wang
  • PEPTIDES AS ACTIVE AGENTS TO STABILIZE BIOLOGICAL BARRIERS
    Publication number: 20130143791
    Abstract: The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema.
    Type: Application
    Filed: June 17, 2011
    Publication date: June 6, 2013
    Applicant: XiberScience GmbH
    Inventors: Peter Petzelbauer, Sonja Reingruber
  • Modified therapeutic agents
    Patent number: 8455447
    Abstract: The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 4, 2013
    Assignee: Adprotech Limited
    Inventors: Dirk Esser, Jason Richard Betley, Simon Hugh Ridley
  • Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
    Patent number: 8455450
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: June 4, 2013
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY
    Publication number: 20130136742
    Abstract: Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.
    Type: Application
    Filed: February 1, 2013
    Publication date: May 30, 2013
    Inventors: Kyunglim LEE, Youngjoo Kwon, Miyoung Kim, Moonhee Kim
  • Fusion proteins of collagen-binding domain and parathyroid hormone
    Patent number: 8450273
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: May 28, 2013
    Assignees: The Board of Trustees of the University of Arkansas, Ochsner Clinic Foundation, National University Corporation Kagawa University
    Inventors: Joshua Sakon, Robert C. Gensure, Osamu Matsushita
  • Collagen peptide having immune-enhancing activity from and preparation method and uses thereof
    Patent number: 8450100
    Abstract: A collagen peptide with immune-enhancing activity from Cyanea nozakii, and a preparation method thereof are provided. The collagen peptide contains 80-90 wt % of proteins and 10-20 wt % of sugars, and has an average molecular weight of 1,000-3,000 Dalton. Monosaccharide contained in the collagen peptide are mainly glucose, glycine accounts for 16% or above and the sum of proline and hydroxyproline accounts for 18% or above of amino acids contained therein. The collagen peptide is capable of being used for preparation of medicines, health products, and skincare cosmetics having immune-enhancing function.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: May 28, 2013
    Assignees: Jiangnan University
    Inventors: Luhong Tang, Bentian Zhang, Chao Deng, Dan Lin, Qi Wang, Wei Chen
  • Immunoregulatory peptides and methods of use
    Patent number: 8450285
    Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 28, 2013
    Assignee: 13Therapeutics, Inc.
    Inventors: Sharon L. McCoy, Steven H. Hefeneider
  • PREVENTION AND TREATMENT OF CAST NEPHROPATHY
    Publication number: 20130129714
    Abstract: Provided herein are polypeptides comprising or consisting essentially of a QSYDNTLSGSYVF (SEQ ID NO:1) or LSADSSGSYLYVF (SEQ ID NO:2) amino acid sequence. Also provided herein are methods of treating or preventing cast nephropathy in a subject. The methods comprise identifying a subject with or at risk of developing cast nephropathy and administering to the subject any of the polypeptides disclosed herein.
    Type: Application
    Filed: April 1, 2011
    Publication date: May 23, 2013
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventor: Paul W. Sanders
  • COMPOSITIONS AND METHODS TO DETECT VARIOUS INFECTIOUS ORGANISMS
    Publication number: 20130129764
    Abstract: The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm (Dirofilaria immitis), Ehrlichia Canis, Anaplasma phagocytophilum, and Borrelia burgdorferi. More particularly, this invention relates to antibodies that bind to a heartworm antigen, the E. Canis gp36 polypeptide, the A. phagocytophilum p44 polypeptide, the B. burgdorferi OspA, OspC, OspF, p39, p41 and VlsE polypeptides, and uses thereof.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 23, 2013
    Applicant: VCA Antech, Inc.
    Inventor: VCA Antech, Inc.
  • Peptide Derivatives for Biofunctionalization of Silicon Substrates and Their Applications
    Publication number: 20130131314
    Abstract: The present invention relates to the use of a peptide consisting of 5 to 30 amino acid residues comprising an amino acid sequence selected from LLADTTHHRPWT (SEQ ID NO: 1), SPGLSLVSHMQT (SEQ ID NO: 2), and the sequences presenting at least 80% identity with SEQ ID NO: 1 or SEQ ID NO: 2, for the funcfionalization of silicon substrate. The present invention also relates to the specific peptides as such, and to silicon substrates functionalized by the adsorption on their surface of such specific peptides. Finally, the present invention is also directed to a process for the preparation of such functionalized silicon substrates, and to articles comprising a silicon substrate according to the invention.
    Type: Application
    Filed: May 5, 2011
    Publication date: May 23, 2013
    Applicants: UNIVERSITE MONTPELLIER I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Csilla Gergely, Elias Estephan, Marie-Belle Saab, Christian Larroque, Frédéric Cuisinier
  • EIF4E BINDING PEPTIDES
    Publication number: 20130130989
    Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
    Type: Application
    Filed: April 27, 2011
    Publication date: May 23, 2013
    Inventors: Christopher John Brown, Cheng San Brian Chia
  • Markers for Renal Disease
    Publication number: 20130130285
    Abstract: This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.
    Type: Application
    Filed: June 3, 2011
    Publication date: May 23, 2013
    Applicant: IDEXX LABORATORIES, INC.
    Inventors: Michael Randolph Atkinson, Mahalakshmi Yerramilli, Murthy V.S.N. Yerramilli
  • EPITOPES OF THE HUMAN PDGF RECEPTOR ABLE TO BIND HUMAN AUTO-ANTIBODIES, ANTIBODIES AND USES THEREOF
    Publication number: 20130130268
    Abstract: The present invention refers to peptides comprised in the extracellular region of human PDGF receptor (hPDGFR) alpha, their use for detecting auto-antibodies anti-hPDGFR alpha and to a method for the diagnosis or the monitoring control for therapy of SSc. The present invention also refers to antibodies or recombinant or synthetic derivatives thereof able to recognize and bind to the above peptide and to their use in the treatment of SSc.
    Type: Application
    Filed: July 29, 2011
    Publication date: May 23, 2013
    Inventors: Gianluca Moroncini, Ada Funaro, Armando Gabrielli, Vittorio Enrico Avvedimento, Silvia Svegliati Baroni, Mariarosaria Santillo, Roberto Paterno'
  • NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B
    Publication number: 20130129740
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Application
    Filed: August 30, 2012
    Publication date: May 23, 2013
    Applicants: J. Craig Venter Institute, Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Hervé Tettelin, Claire Fraser
  • USE OF ANTI-PLAC1 PROTEIN ANTIBODIES AS BIOMARKERS OF INFERTILITY, DIAGNOSTIC KIT FOR THE DETECTION OF THE IMMUNE RESPONSE AGAINST PLAC1 AND USE OF PLAC1 PROTEIN IN THERAPEUTIC AND CONTRACEPTIVE FIELDS
    Publication number: 20130129715
    Abstract: Use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in therapeutic and contraceptive fields The present invention concerns the use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in tolerogenic or immunogenic form in the therapy for infertility or as contraceptive or post-coital interception means, respectively.
    Type: Application
    Filed: July 13, 2011
    Publication date: May 23, 2013
    Inventors: Arcangelo Liso, Maria Matteo
  • TARGETING SIGNAL FOR INTEGRATING PROTEINS, PEPTIDES AND BIOLOGICAL MOLECULES INTO BACTERIAL MICROCOMPARTMENTS
    Publication number: 20130133102
    Abstract: A conserved region of sequence in bacterial microcompartment (BMC) enzymes and proteins was identified. Peptide sequences derived from this conserved region of native BMC proteins and enzymes appear to target the hexameric facets of BMC shell proteins. These peptides were predicted to share general properties of a predicted alpha helical conformation, flanked by poorly conserved segment(s) of primary structure); for each type of encapsulated protein, and for each functionally distinct BMC. These peptides can be used as targeting signals for integrating biomolecules and molecules into bacterial microcompartments or for attaching molecules or biomolecules to native or non-native bacterial microcompartment shell proteins.
    Type: Application
    Filed: August 1, 2012
    Publication date: May 23, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Cheryl A. Kerfeld, James N. Kinney
  • HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS
    Publication number: 20130129725
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: April 13, 2011
    Publication date: May 23, 2013
    Inventors: Roger Fachínì, Ian Foltz, Seog Joon Han, Susie Miki Harris, Shaw-Fen Sylvia Hu, Chadwick Terence King, Yang Li, Ji Lu, Mark Leo Michaels, Jeonghoon Sun
  • Peptide having bindability with adiponectin, analysis method utilizing same peptide, and analysis device utilizing same peptide
    Patent number: 8445633
    Abstract: Developed is an adiponectin-recognition material which is inexpensive and excellent in: productivity; stability of quality and a structure; and convenience. The present invention provides a peptide consisting of not more than 50 amino acids and having bindability with adiponectin.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Sharp Kabushiki Kaisha
    Inventors: Mao Yamada, Ai Tsutsui, Yoshiro Akagi, Naoya Ichimura, Atsushi Mizusawa, Takakiyo Tada
  • Method and peptide for regulating cellular activity
    Patent number: 8445449
    Abstract: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: May 21, 2013
    Assignees: The United States of America, as represented by the Department of Veterans Affairs, Oregon Health & Science University
    Inventors: Steven H. Hefeneider, Sharon L. McCoy
  • PEPTIDE FOR IMPROVING BIOSTABILITY OF BIOACTIVE SUBSTANCE, AND BIOACTIVE SUBSTANCE HAVING IMPROVED BIOSTABILITY
    Publication number: 20130123460
    Abstract: The present invention aims at providing a peptide fragment capable of improving biostability of a bioactive substance while maintaining the activity of the bioactive substance, and a bioactive substance to which the peptide fragment is added. The present invention relates to a partial peptide of a GA module having 5 to 25 amino acids, including a partial sequence of a GA module (SEQ ID NO: 1) and the amino acid sequence Ile-Asp-Glu-Ile-Leu (SEQ ID NO: 2), and a bioactive complex in which the partial peptide of the GA module is bound to a bioactive substance. The bioactive substance includes GLP-1, GLP-2, GIP, VIP, somatostatin, amylin, ghrelin, derivatives thereof, and the like.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 16, 2013
    Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.
    Inventors: Masayuki Okamoto, Ryuhji Okamoto, Tomohiro Shigemori, Takayo Murase, Atsushi Miyachi, Mitsuaki Takeuchi, Miyuki Tamura, Hiroshi Kinoshita
  • PEPTIDES FOR THE REGULATION OF NEUROTRANSMITTER SEQUESTRATION AND RELEASE
    Publication number: 20130123187
    Abstract: A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises: (a) introducing a plurality of agents into a plurality of cells; and (b) analyzing Vesicular Monoamine Transporter 2 (VMAT2) transcription in the cells; and (c) identifying an agent of the plurality of agents capable of up-regulating DJ-1-dependent VMAT2 transcription in the cells, thereby selecting the agent comprising the neuroprotecting activity.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 16, 2013
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventor: Ramot at Tel-Aviv University Ltd.